Claris Ventures has led a £15.2m series-B round for NeoPhore, a British biotechnology company specialised in cancer immunotherapy.
Fund could tap family offices and wealthy individuals, while the VC's founders have so far invested their own capital
Germany-based IT consultancy is to be Equistone's fourth platform investment of 2021
Avenir, Accel, Bessemer Venture Partners, General Catalyst and Iris Capital also take part in the round
YielCo Special Situations Europe II is targeting €300m; YielCo Defensive Investments targets €150m